Bms-986511
Phase 2
Bristol-Myers SquibbBms-986511 is one of 47 therapeutic programs targeting Major Depressive Disorder. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
46
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
120 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Sunosi
AAxsome Therapeutics, Inc.
Phase 3
Lithobid
SSolvay Pharmaceuticals
Phase 3
Clozaril
LLife Extension Foundation Inc.
Phase 3
Psilocybin
COMPASS PathwaysPhase 3
Esketamine Hydrochloride
TThe Second Hospital of Anhui Medical University
Phase 3
Aticaprant
Johnson & JohnsonPhase 3
Selective Serotonin Reuptake Inhibitor
Johnson & JohnsonPhase 3
CYB003
CCybin IRL Limited
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Major Depressive Disorder1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Bms-986511. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company